Having trouble accessing articles? Reset your cache.

Alimta pemetrexed: Phase III data

A placebo-controlled, international Phase III trial in 795 patients showed that Alimta plus cisplatin every 3 weeks missed the primary endpoint of significantly

Read the full 233 word article

User Sign In

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE